Data from Two Mipomersen Phase 3 Trials Presented at ACC.

Business Wire › April 05, 2011

Linked as:

Extract

Data from Two Mipomersen Phase 3 Trials Presented at ACC.

Study in Patients with Severe Familial Hypercholesterolemia Meets Primary Endpoint with 36 Percent LDL-C Reduction

CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Genzyme Corp., a subsidiary of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced today that data from two phase 3 studies of mipomersen in patients who had high cholesterol levels while on lipid-lowering therapy were presented at the American College of Cardiology's 60th Annual Scientific Session.

In the study in patients with severe heterozygous familial hypercholesterolemia (heFH), mipomersen reduced LDL-C, the primary endpoint, by 36 percent compared with a 13 percent increase for placebo (p

See the full content of this document